Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

A quarter of patients with type 1 diabetes have co-existing non-islet autoimmunity: the findings of a UK population-based family study.

Kozhakhmetova A, Wyatt RC, Caygill C, Williams C, Long AE, Chandler K, Aitken RJ, Wenzlau JM, Davidson HW, Gillespie KM, Williams AJK.

Clin Exp Immunol. 2018 Jun;192(3):251-258. doi: 10.1111/cei.13115. Epub 2018 Mar 24.

2.

Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients.

Lahner E, Brigatti C, Marzinotto I, Carabotti M, Scalese G, Davidson HW, Wenzlau JM, Bosi E, Piemonti L, Annibale B, Lampasona V.

Clin Transl Gastroenterol. 2017 Jan 19;8(1):e215. doi: 10.1038/ctg.2016.71.

3.

ATPase4A Autoreactivity and Its Association With Autoimmune Phenotypes in the Type 1 Diabetes Genetics Consortium Study.

Wenzlau JM, Fain PR, Gardner TJ, Frisch LM, Annibale B, Hutton JC.

Diabetes Care. 2015 Oct;38 Suppl 2:S29-36. doi: 10.2337/dcs15-2006.

4.

Changes in Zinc Transporter 8 Autoantibodies Following Type 1 Diabetes Onset: The Type 1 Diabetes Genetics Consortium Autoantibody Workshop.

Wenzlau JM, Frisch LM, Hutton JC, Fain PR, Davidson HW.

Diabetes Care. 2015 Oct;38 Suppl 2:S14-20. doi: 10.2337/dcs15-2004.

5.

Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.

Demeester S, Keymeulen B, Kaufman L, Van Dalem A, Balti EV, Van de Velde U, Goubert P, Verhaeghen K, Davidson HW, Wenzlau JM, Weets I, Pipeleers DG, Gorus FK.

Diabetes Care. 2015 Apr;38(4):644-51. doi: 10.2337/dc14-1575. Epub 2015 Jan 12.

6.

Zinc transporter 8 (ZnT8) and β cell function.

Davidson HW, Wenzlau JM, O'Brien RM.

Trends Endocrinol Metab. 2014 Aug;25(8):415-24. doi: 10.1016/j.tem.2014.03.008. Epub 2014 Apr 18. Review.

7.

Clinical and biological characteristics of diabetic patients under age 40 in Cameroon: relation to autoantibody status and comparison with Belgian patients.

Asanghanwa M, Gorus FK, Weets I, der Auwera BV, Aminkeng F, Mbunwe E, Goubert P, Verhaeghen K, Sobngwi E, Wenzlau JM, Hutton JC, Pipeleers DG, Keymeulen B, Mbanya JC, van Schravendijk C.

Diabetes Res Clin Pract. 2014 Jan;103(1):97-105. doi: 10.1016/j.diabres.2013.11.013. Epub 2013 Nov 20.

8.

Novel diabetes autoantibodies and prediction of type 1 diabetes.

Wenzlau JM, Hutton JC.

Curr Diab Rep. 2013 Oct;13(5):608-15. doi: 10.1007/s11892-013-0405-9. Review.

9.

In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions.

Mbunwe E, Van der Auwera BJ, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, Seret N, Decochez K, Vandemeulebroucke E, Gillard P, Keymeulen B, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetologia. 2013 Sep;56(9):1964-70. doi: 10.1007/s00125-013-2951-8. Epub 2013 May 28.

10.

Proinsulin/Insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity.

Yu L, Dong F, Miao D, Fouts AR, Wenzlau JM, Steck AK.

Diabetes Care. 2013 Aug;36(8):2266-70. doi: 10.2337/dc12-2245. Epub 2013 Feb 19.

11.

Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients.

Gorus FK, Balti EV, Vermeulen I, Demeester S, Van Dalem A, Costa O, Dorchy H, Tenoutasse S, Mouraux T, De Block C, Gillard P, Decochez K, Wenzlau JM, Hutton JC, Pipeleers DG, Weets I; Belgian Diabetes Registry.

Clin Exp Immunol. 2013 Jan;171(1):82-90. doi: 10.1111/j.1365-2249.2012.04675.x.

12.

HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients.

Mbunwe E, Van der Auwera BJ, Vermeulen I, Demeester S, Van Dalem A, Balti EV, Van Aken S, Derdelinckx L, Dorchy H, De Schepper J, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry.

Diabetes. 2013 Apr;62(4):1345-50. doi: 10.2337/db12-0747. Epub 2012 Nov 16.

13.

Extrapancreatic autoantibody profiles in type I diabetes.

Burbelo PD, Lebovitz EE, Bren KE, Bayat A, Paviol S, Wenzlau JM, Barriga KJ, Rewers M, Harlan DM, Iadarola MJ.

PLoS One. 2012;7(9):e45216. doi: 10.1371/journal.pone.0045216. Epub 2012 Sep 21.

14.

Genetic association of zinc transporter 8 (ZnT8) autoantibodies in type 1 diabetes cases.

Howson JM, Krause S, Stevens H, Smyth DJ, Wenzlau JM, Bonifacio E, Hutton J, Ziegler AG, Todd JA, Achenbach P.

Diabetologia. 2012 Jul;55(7):1978-84. doi: 10.1007/s00125-012-2540-2. Epub 2012 Apr 12.

15.

Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies.

Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2012 Jun;35(6):1213-8. doi: 10.2337/dc11-2081. Epub 2012 Mar 23.

16.

Development of a novel autoantibody assay for autoimmune gastritis in type 1 diabetic individuals.

Wenzlau JM, Gardner TJ, Frisch LM, Davidson HW, Hutton JC.

Diabetes Metab Res Rev. 2011 Nov;27(8):887-90. doi: 10.1002/dmrr.1267.

17.

Mapping of conformational autoantibody epitopes in ZNT8.

Wenzlau JM, Frisch LM, Hutton JC, Davidson HW.

Diabetes Metab Res Rev. 2011 Nov;27(8):883-6. doi: 10.1002/dmrr.1266.

18.

Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8.

Lampasona V, Schlosser M, Mueller PW, Williams AJ, Wenzlau JM, Hutton JC, Achenbach P.

Clin Chem. 2011 Dec;57(12):1693-702. doi: 10.1373/clinchem.2011.170662. Epub 2011 Oct 6.

19.

Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age.

Vermeulen I, Weets I, Asanghanwa M, Ruige J, Van Gaal L, Mathieu C, Keymeulen B, Lampasona V, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetes Care. 2011 Aug;34(8):1760-5. doi: 10.2337/dc10-2268. Epub 2011 Jun 29.

20.

Human type 1 diabetes is associated with T cell autoimmunity to zinc transporter 8.

Dang M, Rockell J, Wagner R, Wenzlau JM, Yu L, Hutton JC, Gottlieb PA, Davidson HW.

J Immunol. 2011 May 15;186(10):6056-63. doi: 10.4049/jimmunol.1003815. Epub 2011 Apr 6.

21.

The diagnostic value of zinc transporter 8 autoantibody (ZnT8A) for type 1 diabetes in Chinese.

Yang L, Luo S, Huang G, Peng J, Li X, Yan X, Lin J, Wenzlau JM, Davidson HW, Hutton JC, Zhou Z.

Diabetes Metab Res Rev. 2010 Oct;26(7):579-84. doi: 10.1002/dmrr.1128.

22.

Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects.

Wenzlau JM, Walter M, Gardner TJ, Frisch LM, Yu L, Eisenbarth GS, Ziegler AG, Davidson HW, Hutton JC.

J Clin Endocrinol Metab. 2010 Oct;95(10):4712-9. doi: 10.1210/jc.2010-0169. Epub 2010 Jul 7.

23.

Novel antigens in type 1 diabetes: the importance of ZnT8.

Wenzlau JM, Frisch LM, Gardner TJ, Sarkar S, Hutton JC, Davidson HW.

Curr Diab Rep. 2009 Apr;9(2):105-12. Review.

PMID:
19323954
24.

SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes.

Wenzlau JM, Moua O, Sarkar SA, Yu L, Rewers M, Eisenbarth GS, Davidson HW, Hutton JC.

Ann N Y Acad Sci. 2008 Dec;1150:256-9. doi: 10.1196/annals.1447.029.

PMID:
19120307
25.

Identification of a major humoral epitope in Slc30A8 (ZnT8).

Wenzlau JM, Moua O, Liu Y, Eisenbarth GS, Hutton JC, Davidson HW.

Ann N Y Acad Sci. 2008 Dec;1150:252-5. doi: 10.1196/annals.1447.028.

PMID:
19120306
26.

Conserved epitopes in the protein tyrosine phosphatase family of diabetes autoantigens.

Liu Y, Wenzlau JM, Yu L, Patel C, Eisenbarth GS, Hutton JC, Davidson HW.

Ann N Y Acad Sci. 2008 Dec;1150:245-7. doi: 10.1196/annals.1447.035.

PMID:
19120304
27.

Association between anti-ZnT8 autoantibody specificities and SLC30A8 Arg325Trp variant in Japanese patients with type 1 diabetes.

Kawasaki E, Uga M, Nakamura K, Kuriya G, Satoh T, Fujishima K, Ozaki M, Abiru N, Yamasaki H, Wenzlau JM, Davidson HW, Hutton JC, Eguchi K.

Diabetologia. 2008 Dec;51(12):2299-302. doi: 10.1007/s00125-008-1165-y. Epub 2008 Oct 11.

PMID:
18850084
28.

New antigenic targets in type 1 diabetes.

Wenzlau JM, Hutton JC, Davidson HW.

Curr Opin Endocrinol Diabetes Obes. 2008 Aug;15(4):315-20. doi: 10.1097/MED.0b013e328308192b. Review.

PMID:
18594270
29.

A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes.

Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S, Walters J, Eisenbarth GS, Davidson HW, Hutton JC.

Diabetes. 2008 Oct;57(10):2693-7. doi: 10.2337/db08-0522. Epub 2008 Jun 30.

30.

The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes.

Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC.

Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17040-5. Epub 2007 Oct 17.

31.

Embryonic growth-associated protein is one subunit of a novel N-terminal acetyltransferase complex essential for embryonic vascular development.

Wenzlau JM, Garl PJ, Simpson P, Stenmark KR, West J, Artinger KB, Nemenoff RA, Weiser-Evans MC.

Circ Res. 2006 Mar 31;98(6):846-55. Epub 2006 Feb 16.

PMID:
16484612
32.

Extracellular ATP-induced proliferation of adventitial fibroblasts requires phosphoinositide 3-kinase, Akt, mammalian target of rapamycin, and p70 S6 kinase signaling pathways.

Gerasimovskaya EV, Tucker DA, Weiser-Evans M, Wenzlau JM, Klemm DJ, Banks M, Stenmark KR.

J Biol Chem. 2005 Jan 21;280(3):1838-48. Epub 2004 Nov 1.

33.

Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN.

Mourani PM, Garl PJ, Wenzlau JM, Carpenter TC, Stenmark KR, Weiser-Evans MC.

Circulation. 2004 Mar 16;109(10):1299-306. Epub 2004 Mar 1.

PMID:
14993145
34.

Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor PTEN.

Garl PJ, Wenzlau JM, Walker HA, Whitelock JM, Costell M, Weiser-Evans MC.

Circ Res. 2004 Feb 6;94(2):175-83. Epub 2003 Dec 1.

PMID:
14656929
35.

cDNA cloning of the two subunits of human CAAX farnesyltransferase and chromosomal mapping of FNTA and FNTB loci and related sequences.

Andres DA, Milatovich A, Ozçelik T, Wenzlau JM, Brown MS, Goldstein JL, Francke U.

Genomics. 1993 Oct;18(1):105-12.

PMID:
8276393
36.
37.

A latent intron-encoded maturase is also an endonuclease needed for intron mobility.

Wenzlau JM, Saldanha RJ, Butow RA, Perlman PS.

Cell. 1989 Feb 10;56(3):421-30.

PMID:
2536592

Supplemental Content

Loading ...
Support Center